Negative in Ames (parent and ARV-473), in vitro human lymphocyte micronucleus and in vivo rat micronucleus assays
“Vepdegestrant and its major metabolite ARV-473 did not induce mutations in the bacterial reverse mutation (Ames) assay. Vepdegestrant was not clastogenic in the in vitro human lymphocyte micronucleus assay or in the in vivo micronucleus study in rats.”
✓ VerifiedFDA multi-discipline review, p. 49Source ↗
Carcinogenicity
6-month rasH2 mouse: no statistically significant ovarian tumors up to 800 mg/kg/day
“Administration of ARV-471 did not result in statistically significant ovarian tumors in transgenic rasH2 mice at daily doses up to 800 mg/kg/day for 6 months.”
✓ VerifiedFDA multi-discipline review, p. 73Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Pilot rat EFD: embryo-fetal mortality at ≥30 mg/kg/day (0.3x human AUC)
“Oral administration of vepdegestrant resulted in embryo-fetal mortality (increased resorptions, post-implantation loss and reduced number of live fetuses) at ≥30 mg/kg/day (0.3 times the human AUC at the recommended dose).”
✓ VerifiedFDA multi-discipline review, p. 49Source ↗
Safety pharmacology
No adverse cardiovascular, respiratory or FOB effects in rats and dogs
“Vepdegestrant did not demonstrate adverse cardiovascular, respiratory, or functional observational battery (FOB) effects in standalone safety pharmacology studies or repeated-dose toxicology studies in rats and dogs at the tested doses.”
✓ VerifiedFDA multi-discipline review, p. 48Source ↗
Genotox: Ames
Negative (vepdegestrant and metabolite ARV-473)
“Vepdegestrant and its major metabolite ARV-473 did not induce mutations in the bacterial reverse mutation (Ames) assay.”
✓ VerifiedFDA multi-discipline review, p. 49Source ↗
Genotox: in vitro mammalian
Human lymphocyte micronucleus: negative
“Vepdegestrant was not clastogenic in the in vitro human lymphocyte micronucleus assay or in the in vivo micronucleus study in rats.”
✓ VerifiedFDA multi-discipline review, p. 49Source ↗
Genotox: in vivo
Rat micronucleus: negative
“Vepdegestrant was not clastogenic in the in vitro human lymphocyte micronucleus assay or in the in vivo micronucleus study in rats.”
✓ VerifiedFDA multi-discipline review, p. 49Source ↗
Carcinogenicity model
6-month Tg rasH2 mouse (not required under ICH S9 for advanced cancer)
“Carcinogenicity studies are not warranted to support marketing for therapeutics intended to treat patients with advanced cancer per ICH S9. However, a pivotal 6-month carcinogenicity study in rasH2 mice was conducted”
✓ VerifiedFDA multi-discipline review, p. 72Source ↗
Carcinogenicity timing
26-week rasH2 mouse study completed and included in the NDA submission
“In this submission the sponsor included Study 8500921 “A 26-Week Once or Twice Daily Oral Gavage Carcinogenicity Study with ARV-471 (PF-07850327) in Transgenic RasH2 Mice” with the electronic SEND datasets and Tumor.xpt files.”
✓ VerifiedFDA multi-discipline review, p. 284Source ↗
hERG / QT
No hERG effect up to 30 µM (>1000-fold free Cmax at clinical dose)
“Vepdegestrant had no effect on hERG tail current at concentrations up to 30 µM (the limit of solubility) when compared with vehicle-treated cells. This represents greater than 1000-fold the Cmax of free vepdegestrant at the recommended clinical dose, given that the free fraction is less than 1%.”
✓ VerifiedFDA multi-discipline review, p. 53Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative